Cancer Care


Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen (AVERT)
Principal Investigator (?)
Study Number
Severe nausea and/or vomiting in patients receiving radiotherapy to the upper abdomen is
common despite having received pre-medication with ondansetron, a standard preventive
treatment. This study aims to reduce the incidence of significant nausea and/or vomiting
with the addition of the NK1-antagonist aprepitant to standard ondansetron treatment. This
study will also assess the safety and tolerability of prolonged administration of aprepitant
over the 4 to 6 week period of radiation treatment.
Phase (?)
Phase II
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.